Thirty-seven studies in the literature focused on lncRNAs as biomarkers for predicting response to CRC therapy, and in these papers, the results suggested that MEG3, CACS15, GAS5, and LUCAT1, which are lncRNAs, are biomarkers for drug therapy. This evidence concerns the gene MEG3 and colorectal carcinoma.